• 1
    Albertsen P,Hanley J,Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA. 2005; 293: 20952101.
  • 2
    Albertsen JL,Hanley JA,Gleason DF. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA. 1998; 280: 975.
  • 3
    Partin AW,Mangold LA,Lamm DM,Walsh PC,Epstein JI,Pearson JD. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology. 2001; 58: 843848.
  • 4
    Shipley WU,Thames HD,Sandler HM, et al. Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA. 1999; 281: 15981604.
  • 5
    Tewari A,Johnson CC,Divine G, et al. Long-term survival probability in men with clinically localized prostate cancer: a case-control, propensity modeling study stratified by race, age, treatment and comorbidities. J Urol. 2004; 171: 15131519.
  • 6
    Cuzick J,Fisher G,Kattan M, et al. Long-term outcome among men with conservatively treated localized prostate cancer. Br J Cancer. 2006; 95: 11861194.
  • 7
    Deshmukh N,Foster C. Grading Prostate Cancer. Philadelphia: WB Saunders; 1997.
  • 8
    Harrell FEJr,Lee KL,Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996; 15: 361387.
  • 9
    Harrell FEJr. Regression Modeling Strategies With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York: Springer; 2001.
  • 10
    Eastham JA,Groshen SL,Kattan MW, et al. Fifteen-year survival and recurrence rates after radiotherapy for localized prostate cancer. J Clin Oncol. 1997; 15: 32143222.
  • 11
    Kattan MW. Nomograms are superior to staging and risk grouping systems for identifying high-risk patients: preoperative application in prostate cancer. Curr Opin Urol. 2003; 13: 111116.